Liposomes comprising a calcium phosphate-containing precipitate
View Patent ↗Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.
1. A delivery system complex comprising a biodegradable ionic precipitate wherein, said biodegradable ionic precipitate comprises, i. a salt that comprises a divalent cation; and ii. a bioactive compound, wherein said biodegradable ionic precipitate is encapsulated by a lipid bilayer membrane, wherein;
said lipid bilayer membrane comprises an inner leaflet and an outer leaflet, wherein said inner leaflet comprises a first lipid that is a non-cationic lipid and said outer leaflet comprises a second lipid, wherein said lipid bilayer membrane is asymmetric, and
said first lipid is capable of forming ionic interactions with said biodegradable ionic precipitate.
2. The delivery system of claim 1 , further comprising a lipid-polyethylene glycol (PEG) conjugate, wherein said lipid-PEG conjugate comprises PEG in an amount between about 12 mol % to about 50% of total surface lipid.
3. The delivery system of claim 1 , wherein said bioactive compound is selected from the group consisting of antimicrobials, antibiotics, antimycobacterials, antifungals, antivirals, neoplastic agents, agents affecting the immune response, blood calcium regulators, agents useful in glucose regulation, anticoagulants, antithrombotics, antihyperlipidemic agents, cardiac drugs, thyromimetic and antithyroid drugs, adrenergics, antihypertensive agents, cholinergics, anticholinergics, antispasmodics, antiulcer agents, skeletal and smooth muscle relaxants, prostaglandins, general inhibitors of the allergic response, antihistamines, local anesthetics, analgesics, narcotic antagonists, antitussives, sedative-hypnotic agents, anticonvulsants, antipsychotics, anti-anxiety agents, antidepressant agents, anorexigenics, non-steroidal anti-inflammatory agents, steroidal anti-inflammatory agents, antioxidants, vaso-active agents, bone-active agents, antiarthritics, and diagnostic agents.
4. The delivery system of claim 1 , wherein said bioactive compound is an antiviral or anticancer drug.
5. The delivery system of claim 1 , wherein said bioactive compound is gemcitabine monophosphate.
6. The delivery system of claim 1 , wherein said salt further comprises a trivalent cation.
7. The delivery system of claim 1 , wherein said salt is calcium phosphate precipitate.
8. The delivery complex of claim 1 , wherein said bioactive compound is phosphorylated.
9. The delivery system complex of claim 1 , wherein said bioactive compound is mono phosphorylated.
10. The delivery system complex of claim 1 , wherein said bioactive compound comprises a polynucleotide or a polypeptide.
11. The delivery system complex of claim 10 , wherein said polynucleotide comprises an interfering RNA.
12. The delivery system complex of claim 10 , wherein said polynucleotide comprises an siRNA.
13. The delivery system complex of claim 10 , wherein said polynucleotide is a plasmid DNA.
14. The delivery system complex of claim 2 , wherein said lipid-PEG conjugate comprises a PEG molecule having a molecular weight of about 2000-5000g/mol.
15. The delivery system complex of claim 14 , wherein said lipid-PEG conjugate comprises a 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-carboxy-polyethylene glycol 2000 (DSPE-PEG 2000 ).
16. The delivery system complex of claim 1 , wherein said outer leaflet comprises a targeting ligand.
17. The delivery system complex of claim 16 , wherein said targeting ligand is selected from the group consisting of asialoglycoprotein, insulin, low density lipoprotein (LDL), folate, benzamide derivatives, peptides comprising the arginine-glycine-aspartate (RGD) sequence, and monoclonal and polyclonal antibodies directed against cell surface molecules or mixtures thereof.
18. The delivery system complex of claim 17 , wherein said benzamide derivative comprises anisamide.
19. The delivery system complex of claim 1 , wherein said delivery system complex has a diameter of about 15 to about 120 nm.
20. The delivery system complex of claim 1 , wherein said delivery system complex has a diameter of about 25 to about 30 nm.
21. The delivery system complex of claim 1 , wherein said second lipid is a cationic lipid.
22. The delivery system complex of claim 21 , wherein said second lipid is DOTAP.
23. A method of making the delivery system complex of claim 1 , comprising
a) mixing a first reverse microemulsion comprising a metal chloride and a second reverse microemulsion comprising a metal phosphate and said first lipid having a free phosphate group to form said biodegradable ionic precipitate, encapsulating said precipitate with said first lipid, and wherein said bioactive compound is present in said first reverse microemulsion or said second reverse microemulsion;
b) washing said biodegradable ionic precipitate;
c) solubilizing said biodegradable ionic precipitate in a volatile, organic solvent to form a biodegradable ionic precipitate/solvent mixture;
d) adding said second lipid to said biodegradable ionic precipitate/solvent mixture; and
e) evaporating said volatile organic solvent to produce said delivery system complex.
24. The delivery system complex of claim 10 , wherein said polynucleotide comprises a mRNA.
25. The delivery system complex of claim 10 , wherein said polynucleotide comprises a miRNA.
26. The delivery system complex of claim 10 , wherein said polynucleotide comprises non-coding RNA.
27. The delivery system complex of claim 1 , wherein said inner leaflet comprises a phosphatidic acid.